RYM

RYTHM is not a company you can underwrite on the numbers — it's a serial reinventor that has already destroyed a $341M accumulated deficit and is now a hemp-derived THC CPG play (Señorita beverages, incredibles, Beboe) after divesting both its extraction business (exited March 2025) and cultivation/VFU business (sold Dec 2024) into discontinued operations. The headline '+95,916.7% revenue growth' to $17.3M is a mirage created by lapping an $18K FY2024 comparable; the real revenue arc is FY2021 $59.9M → FY2022 $58.3M → FY2023 $15.1M → FY2024 $18K → FY2025 $17.3M, i.e. a business that keeps blowing up and starting over. Gross margin is a respectable 59%, but SG&A of $34.1M plus an $8.5M long-lived-asset impairment drove a -$32.3M operating loss (-187% operating margin) and a -$33.3M net loss (-192% net margin) on just $17.3M of sales. There is no path to profitability visible in this data.

The balance sheet is stressed and the burn is the clock. Equity fell 53.6% to just $13.0M against $93.7M of liabilities (7.19x leverage), and operating cash flow was -$23.5M against $32.2M of cash — roughly a single year of runway before another dilutive raise or worse. Management states outright that the financials are 'prepared assuming that we will continue as a going concern,' the textbook flag that survival is not assured. Diluted EPS was -$16.68 on only 2.15M shares (a post-reverse-split structure), and shares already grew 10.1% year-over-year — dilution is the likely funding mechanism, and at a $54.7M market cap the equity is a thin sliver beneath the debt.